|ENTERPRISE PRODUCTS PARTNERS L P filed this Form 424B5 on 02/02/2018|
Concurrent Subordinated Notes Offering
Concurrent with this offering, we announced the concurrent subordinated notes offering, which we expect will price concurrently with the pricing of the notes offered hereby. The junior subordinated notes are being offered in the concurrent subordinated notes offering by means of a separate prospectus supplement and accompanying base prospectus and not by means of this prospectus supplement. The completion of this offering and the completion of the concurrent subordinated notes offering are not conditioned on each other. We estimate that we will receive net proceeds of approximately $691.8 million from the concurrent subordinated notes offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We cannot give any assurance that the concurrent subordinated notes offering will be completed. We anticipate using the net proceeds from the concurrent subordinated notes offering for the repurchase or redemption of all or a portion of EPOs outstanding Junior Subordinated Notes B due January 2068 (the Junior Subordinated Notes B) and for general company purposes.
This prospectus supplement is not an offer to sell or a solicitation of an offer to buy the securities being offered in the concurrent subordinated notes offering.
Condensed Financial HighlightsFourth Quarter and Fiscal Year 2017 Results (Unaudited)
The following table sets forth selected financial highlights for the periods indicated (dollars in millions, except per unit amounts):